Hepatocellular Carcinoma and Statins.,Biochemistry

当前位置： X-MOL 学术 › Biochemistry › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hepatocellular Carcinoma and Statins.
Biochemistry ( IF 2.9 ) Pub Date : 2020-08-31 , DOI: 10.1021/acs.biochem.0c00476
Ghazal Alipour Talesh _{1,

2} , Véronique Trézéguet ₁ , Aksam Merched ₁

Affiliation

HMG-CoA reductase inhibitors (known as statins) are commonly prescribed worldwide for the management of coronary heart disease and the underlying dyslipidemia. This class of drugs has been shown to infer a significant decrease in the risk of cardiovascular morbidity and mortality. Only recently though have the beneficial effects of statins in other diseases such as non-alcoholic steatohepatitis been highlighted. Importantly, also, multiple studies have revealed that statin use was associated with lower cancer-associated mortality across multiple types of cancers. This work aims to review those studies with a particular focus on liver cancer. We also provide a review of the proposed mechanisms of action describing how statins can induce chemo-preventive and antitumor effects.

中文翻译：

肝细胞癌和他汀类药物。

HMG-CoA还原酶抑制剂（称为他汀类药物）在世界范围内普遍用于治疗冠心病和潜在的血脂异常。这类药物已显示出可显着降低心血管疾病发病率和死亡率的风险。尽管直到最近才强调了他汀类药物在其他疾病（例如非酒精性脂肪性肝炎）中的有益作用。同样重要的是，多项研究表明，他汀类药物的使用与多种癌症的癌症相关死亡率降低有关。这项工作旨在回顾那些特别关注肝癌的研究。我们还提供了对拟议的作用机制的综述，该机制描述了他汀类药物如何诱导化学预防和抗肿瘤作用。

更新日期：2020-09-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11